1. Home
  2. NEWT vs TRDA Comparison

NEWT vs TRDA Comparison

Compare NEWT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NewtekOne Inc.

NEWT

NewtekOne Inc.

N/A

Current Price

$10.41

Market Cap

310.9M

Sector

Finance

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$5.22

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEWT
TRDA
Founded
1998
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
310.9M
275.3M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
NEWT
TRDA
Price
$10.41
$5.22
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$15.20
★ $18.75
AVG Volume (30 Days)
231.4K
★ 455.7K
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 7.04%
N/A
EPS Growth
★ 11.22
N/A
EPS
★ 1.24
N/A
Revenue
N/A
★ $25,421,000.00
Revenue This Year
$3.63
N/A
Revenue Next Year
$10.99
$550.08
P/E Ratio
$8.71
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.59
$4.11
52 Week High
$15.69
$16.45

Technical Indicators

Market Signals
Indicator
NEWT
TRDA
Relative Strength Index (RSI) 38.26 51.38
Support Level N/A $4.18
Resistance Level $11.61 $5.75
Average True Range (ATR) 0.34 0.50
MACD -0.02 0.14
Stochastic Oscillator 0.42 77.33

Price Performance

Historical Comparison
NEWT
TRDA

About NEWT NewtekOne Inc.

NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: